Shilpa Medicare (SML) has entered into a binding agreement with NXI Therapeutics AG based out of Basel, Switzerland for development, supply of a New Chemical Entity (NCE). Under the terms of the strategic collaboration, SML will support both development - including first-in-human clinical studies - as well as long-term commercial supply with GMP manufacturing. Powered by Capital Market - Live News

Shilpa Medicare has filed its Rotigotine 1, 2, 3, 4, 6, 8 mg/24 h transdermal patch USP, ANDA for US market, marking its first-ever transdermal patch submission to the U.S. Food and Drug Administration (USFDA). This application submitted as an ANDA with USFDA is a generic version of the innovator product Neupro�. Shilpa` s product is pharmaceutical and bioequivalent version of the reference product Neupro�. Shilpa` s Rotigotine patches are indicated for treatment of Restless Legs Syndrome and Parkinson`s disease. The total addressable US market for Rotigotine is estimated at USD 112 million. This Filling represents a significant milestone for the Company, being Shilpa Medicare`s First transdermal patch dosage form, which is a complex dosage form to be filed in the US market. The once-daily, patientfriendly transdermal formulation ensures reproducible, sustained, and controlled release of medication, enhancing patient compliance. This submission has come from the Company`s finished dosage form manufacturing facility, Shilpa Medicare Ltd, Unit VI, located at Dobbaspet, Bengaluru, Karnataka. The facility is involved in manufacturing, packaging, labelling and testing of specialized finished dosage forms as oral dispersible/dissolving Films and Transdermal Patches. Powered by Capital Market - Live News

Net profit of Shilpa Medicare rose 40.28% to Rs 44.58 crore in the quarter ended December 2025 as against Rs 31.78 crore during the previous quarter ended December 2024. Sales rose 28.32% to Rs 409.73 crore in the quarter ended December 2025 as against Rs 319.30 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales409.73319.30 28 OPM %27.8125.26 - PBDT104.0870.42 48 PBT73.7141.61 77 NP44.5831.78 40 Powered by Capital Market - Live News

Shilpa Medicare will hold a meeting of the Board of Directors of the Company on 6 February 2026.Powered by Capital Market - Live News

Shilpa Medicare has received the Initial Authorization from Europe, recommending the grant of the final Marketing Authorization for Shilpa Medicare`s prescription product, Rotigotine 1, 2, 3, 4, 6, 8 mg/24 h transdermal patch. This application, submitted as a generic application via Decentralized Procedure in Europe and is a generic version of the innovator product Neupro�. Shilpa`s product is pharmaceutical and bioequivalent version of the reference product Neupro�. Shilpa`s Rotigotine patches are indicated for treatment of Restless Legs Syndrome and Parkinson`s disease.The total addressable European market for Rotigotine is estimated at ~USD 222 million. Shilpa has on boarded a strategic commercialization partner in Europe, with a targeted launch in FY27. This authorization represents a significant milestone for the Company, being Shilpa Medicare`s First transdermal patch dosage form to receive marketing authorization in the European region. This approval has come from the Company`s finished dosage form manufacturing facility, Shilpa Medicare Ltd, Unit VI, located at Dobbaspet, Bengaluru, Karnataka. This is the first approval of a prescription transdermal dosage Form in the European markets from this facility. The facility is involved in manufacturing, packaging, labelling and testing of specialized finished dosage forms as oral dispersible/dissolving Films and Transdermal Patches. Powered by Capital Market - Live News